Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|March 4, 2023
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumoursMelissa L Johnson, Judy S Wang, Gerald Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR InhibitorDavid S Hong, Kathleen N Moore, Johanna C Bendell, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Investigational New Drugs|April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumorsGerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2024
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid TumorsBabar Bashir, Judy S Wang, Gerald Falchook, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Investigational New Drugs|February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trialAndrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
Pageof 3